The option of discontinuing octreotide in patients well-controlled on low doses offered at long intervals was studied in 12 responders fulfilling the following criteria: single basal GH <1.5 ng/ml and IGF-1 <1.2*ULN, no history of irradiation or recent dopamine agonist use, and tumor remnant <8 mm after discontinuation of octreotide. This evidence concerns the gene GH1 and neoplasm.